The United Kingdom has eased certain sanctions related to Russian oil imports in a move aimed at stabilising rising fuel prices and reducing pressure on energy markets. The decision comes amid continued volatility in global oil supply and concerns over inflation driven by higher energy costs.
According to reports, the revised measures allow more flexibility in specific oil-related transactions while still maintaining broader restrictions linked to the ongoing geopolitical conflict involving Russia. UK officials said the step is intended to balance sanctions enforcement with the need to protect domestic consumers from sharp fuel price increases.
Fuel prices have been climbing in several global markets due to supply uncertainties and shifting trade routes. The easing of some restrictions is expected to slightly improve supply flows and help moderate price pressures in the short term. However, analysts caution that the overall energy market remains sensitive to geopolitical developments and production decisions by major oil-exporting countries.
At the same time, global markets continue to watch inflation trends closely, as energy costs remain a key driver of price levels in many economies. Any sustained rise in oil prices could impact transport, manufacturing, and household expenses.
In a separate development in the pharmaceutical sector, Dr Reddy’s Laboratories has launched oral semaglutide tablets in India under the brand name Obeda. The drug is used for type 2 diabetes management and belongs to the GLP-1 class of medicines, which help control blood sugar and support weight management.
The company has priced the tablet at around ₹99 per unit, aiming to make modern diabetes treatment more affordable and accessible. The oral version offers an alternative to injections, which are commonly used in this drug category.
